Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax + Ruxolitinib in relapsed/refractory myelofibrosis
NCT04468984Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of navitoclax in myelofibrosis (MF), sponsored by AbbVie Inc.. Started Aug 2020; status: active, not recruiting.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04468984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468984.